Logo 1.png
Aeterna Zentaris Set to Regain Full Rights to Macrilen™ (Macimorelin) in U.S. and Canada from Novo Nordisk
August 29, 2022 08:00 ET | Aeterna Zentaris Inc
– Company plans to prioritize efforts to identify new strategic development and commercialization partner – Company is in a strong position that enables it to continue the ongoing pivotal...
logo.png
Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials
August 05, 2022 07:30 ET | Arch Biopartners
TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company targeting acute organ inflammation with...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S: Mim8 phase 1 & 2 data demonstrates potential as once monthly treatment for people with haemophilia A
July 11, 2022 09:45 ET | Novo Nordisk A/S
No thromboembolic events or related serious adverse events reported over 12-week observation period in FRONTIER1 study.1 London, UK, 11 July 2022 – Novo Nordisk announced that the phase 1 & 2...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S: Phase 3 data for concizumab show 86% reduction in treated bleeds in haemophilia A or B with inhibitors
July 10, 2022 10:02 ET | Novo Nordisk A/S
Data presented today show a reduction in treated spontaneous and traumatic bleeds and mean annualised bleeding rate (ABR) of 1.7 with concizumab1 London, UK, 10 July 2022 – Novo Nordisk announced the...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S: Sogroya® data show potential as once-weekly treatment in children living with growth hormone deficiency
June 12, 2022 12:31 ET | Novo Nordisk A/S
Investigational phase 3 data for Sogroya® (somapacitan) injection in children with growth hormone deficiency presented today at the ENDO 2022 Congress1 Atlanta, Georgia (US), 12 June 2022 – Today,...
PureWay® Compliance Partners With Medical Device and Pharmaceutical Manufacturers to Bring Safe and Environmentally Friendly Disposal to Patients At-Home
May 26, 2022 11:00 ET | PureWay® Compliance, Inc.
HOUSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Each year, approximately 9 million patients receive at least 3 billion injections outside of healthcare facilities.  These medications are used to manage a...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S – Share repurchase programme
March 07, 2022 08:08 ET | Novo Nordisk A/S
Bagsværd, Denmark, 7 March 2022 – On 2 February 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
nn_logo_cmyk_blue_small.jpg
Notice for the Annual General Meeting of Novo Nordisk A/S
February 21, 2022 09:05 ET | Novo Nordisk A/S
Bagsværd, Denmark, 21 February 2022 – The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 24 March 2022 at 14.00 (CET) The Annual General Meeting is held as a partially...
nn_logo_cmyk_blue_small.jpg
Novo Nordisk A/S: Share repurchase programme
February 21, 2022 06:09 ET | Novo Nordisk A/S
Bagsværd, Denmark, 21 February 2022 – On 2 February 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
logo.png
Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to include LSALT Peptide (Metablok)
January 04, 2022 07:25 ET | Arch Biopartners
TORONTO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug...